This positive outcome was supported by convergence in ADAS-cog sensitivity analyses (jump-to-reference and ITT), a statistically significant clinical response rate, and a nonsignificant trend towards improved overall function relative to placebo (as measured by the second primary endpoint of ADCS-ADL).
← all excerpts
Masitinib for mild-to-moderate Alzheimer's disease: results from a randomized, placebo-controlled, phase 3, clinical trial.
1
—
—